{
}
DelveInsight's report on Acute Bacterial Skin and Skin-Structure Infections (ABSSSI) forecasts significant market growth by 2034, driven by rising prevalence and awareness. Key players include Glenmark Pharma and AbbVie, with therapies like Zevtera and Dalbavancin leading the charge. The report highlights a higher incidence in men and notes nearly 870,000 hospital admissions in the U.S. due to ABSSSI in 2004.
Wockhardt Limited
Companies
The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
emerging therapies and market dynamics for acute bacterial skin infections
Merck & Co., Inc.
Wockhardt Limited
Pfizer Inc.
Glenmark Pharmaceuticals Limited
Allergan plc
Novartis AG
JPN
FRA
GBR
ESP
USA
DEU
ITA
Gaurav Bora
Show more
19:35 23.12.2024
Trending
Subcategory
Industry Trends
Corporate News
Global Trade Developments
Government Economic Policies
Supply Chain Management
Startups & Entrepreneurship
Retail and Consumer Goods
Energy Sector Developments
Emerging Startups
Funding Rounds & Investments
Industry Mergers & Acquisitions
Banking & Investment Regulations
Cryptocurrency & Blockchain Regulations
Stock Market Updates
Anti-Money Laundering (AML) Regulations
Tax Policy & Corporate Taxation
CEO Changes
Foreign Exchange Rates
Financial Scams and Security
Finance Mergers & Acquisitions
Countries:
Companies:
Apple Inc.
Learning Resources Inc.
MGA Entertainment Inc.
State Street Global Advisors Luxembourg SICAV - SSGA EMU ESG Screened Equity Fund
European Union Bonds
SLB 4,6% 01JUN25
Equinor Ventures AS
Quanta Services, Inc.
Gold Circuit Electronics Ltd.
Unimicron Technology Corp.
Yatra Online, Inc.
Daiwa Institute OF Research Ltd.
Pegatron Corporation
KODEX India Tata Group
Wistron Corporation
Foxconn Technology Co., Ltd.
Volkswagen AG
XIAOMI-W
XPeng Inc.
Tesla, Inc.
Currencies:
United States Dollar
Chinese Yuan
Indian Rupee
United Arab Emirates Dirham
Vietnamese Đồng
New Taiwan Dollar
Japanese Yen
Euro
Australian Dollar
Thai Baht
Saudi Riyal
People: